Burzynski Research Institute (BZYR) Tax Provisions (2011 - 2025)
Burzynski Research Institute (BZYR) posted Tax Provisions of -$138666.0 for Q4 2025, down 97.78% sequentially from -$70112.0 in Q3 2025, and down 87.46% YoY from -$1.1 million in Q4 2024.
Burzynski Research Institute (BZYR) Tax Provisions (2011 - 2025) Analysis & Trends
Burzynski Research Institute has reported Tax Provisions for 8 years, with the latest figure at -$138666.0 in Q4 2025.
- Quarterly Tax Provisions fell 87.46% year-over-year to -$138666.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was -$360414.0 (down 52.43% YoY) and the FY2024 annual result came in at -$2394.0, down 176.34% from the prior year.
- Tax Provisions declined to -$138666.0 in Q4 2025 per BZYR's latest filing, from -$70112.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $13869.0 in Q3 2023 and troughed at -$138666.0 in Q4 2025.
- A 4-year average of -$49383.0 and a median of -$65233.5 in 2023 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2023 and 2024: Tax Provisions soared 363.72% in 2023, then plunged 660.0% in 2024.
- Over 4 years, Tax Provisions stood at -$5259.0 in 2022, then soared by 363.72% to $13869.0 in 2023, then tumbled by 633.35% to -$73970.0 in 2024, then slumped by 87.46% to -$138666.0 in 2025.
- According to Business Quant data, Tax Provisions over the past three periods registered -$138666.0, -$70112.0, and -$73970.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -138,666.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -138,666.00 |
| Aug 31, 2025 | -70,112.00 |
| Nov 30, 2024 | -73,970.00 |
| Aug 31, 2024 | -77,666.00 |
| May 31, 2024 | -77,980.00 |
| Feb 29, 2024 | -6,827.00 |
| Aug 31, 2023 | 13,869.00 |
| May 31, 2023 | -60,355.00 |
| Feb 28, 2023 | 3,136.00 |
| Aug 31, 2022 | -5,259.00 |
| May 31, 2014 | -285,902.00 |
| Nov 30, 2013 | -334,175.00 |
| Aug 31, 2013 | 14,464.00 |
| May 31, 2013 | 16,553.00 |
| Feb 28, 2013 | -2.14 Mn |
| Nov 30, 2012 | -520,112.00 |
| Aug 31, 2012 | -610,019.00 |
| Feb 29, 2012 | -2.43 Mn |
| Aug 31, 2011 | -606,905.00 |